Results from the Estonian postmenopausal hormone therapy trial [ISRCTN35338757]

Maturitas

Volumn 55, Issue 2, 2006, Pages 162-173

  Veerus, Piret ^a,b,e   Hovi, Sirpa Liisa ^c,e   Fischer, Krista ^d   Rahu, Mati ^a,b   Hakama, Matti ^e   Hemminki, Elina ^b  

^a NATIONAL INSTITUTE FOR HEALTH DEVELOPMENT   (Estonia)

^b Estonian Centre of Behavioral and Health Sciences   (Estonia)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY OF TARTU   (Estonia)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Follow up by means of database linkages; Postmenopausal hormone therapy; Randomised trial with blind and non blind controls

Indexed keywords

CONJUGATED ESTROGEN PLUS MEDROXYPROGESTERONE ACETATE; PLACEBO;

ADULT; ARTICLE; CANCER; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ESTONIA; FEMALE; FOLLOW UP; FRACTURE; HEALTH CENTER; HORMONAL THERAPY; HUMAN; ISCHEMIC HEART DISEASE; ORAL CONTRACEPTION; POSTMENOPAUSE; RANDOMIZED CONTROLLED TRIAL; STRATIFICATION; TIME;

AGED; BODY MASS INDEX; CEREBROVASCULAR DISORDERS; COHORT STUDIES; CORONARY DISEASE; DOUBLE-BLIND METHOD; EDUCATIONAL STATUS; ESTONIA; FEMALE; FOLLOW-UP STUDIES; FRACTURES, BONE; HORMONE REPLACEMENT THERAPY; HUMANS; MIDDLE AGED; NEOPLASMS; POSTMENOPAUSE; PROPORTIONAL HAZARDS MODELS; SMOKING; TIME FACTORS;

EQUIDAE;

EID: 33748121955     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2006.01.012     Document Type: Article

References (40)

1. Hulley S., Grady D., Bush T., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280 (1998) 605-613
2. Grady D., Herrington D., Bittner V., et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/Progestin Replacement Study follow up (HERS II). JAMA 288 (2002) 49-57
3. The ESPRIT Team. Oestrogen therapy for prevention of reinfarction in postmenopausal women: a randomised placebo controlled trial. Lancet 360 (2002) 2001-2008
4. Clarke S.C., Kelleher J., Lloyd-Jones H., Slack M., and Schofield P.M. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J Obstet Gynaecol 109 (2002) 1056-1062
5. Herrington D.M., Reboussin D.M., Brosnihan K.B., et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 343 (2000) 522-529
6. Waters D.D., Alderman E.L., Hsia J., et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women. A randomized controlled trial. JAMA 288 (2002) 2432-2440
7. Hodis H.N., Mack W.J., Azen S.P., et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 349 (2003) 535-545
8. Viscoli C.M., Brass L.M., Kernan W.N., Sarrel P.M., Suissa S., and Horwitz R.I. A clinical trial of estrogen-replacement therapy after ischemic stroke. N Engl J Med 345 (2001) 1243-1249
9. Hoibraaten E., Qvigstad E., Arnesen H., Larsen S., Wickstrom E., and Sandset P.M. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: results of the randomised, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost 84 (2000) 961-967
10. Hulley S., Furberg C., Barrett-Connor E., et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA 288 (2002) 58-66
11. Grady D., Wenger N.K., Herrington D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease: the heart and estrogen/progestin replacement study. Ann Intern Med 132 (2000) 689-696
12. Kanaya A.M., Herrington D., Vittinghoff E., et al. Glycemic effects of postmenopausal hormone therapy: the heart and estrogen/progestin replacement study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 138 (2003) 1-9
13. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
14. Manson J.E., Hsia J., Johnson K.C., et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349 (2003) 523-534
15. Wassertheil-Smoller S., Hendrix S.L., Limacher M., et al. Effects of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 289 (2003) 2673-2684
16. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women. The Women's Health Initiative randomized trial. JAMA 289 (2003) 3243-3253
17. Shumaker S., Legault C., Rapp S., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2651-2662
18. Cauley J.A., Robbins J., Chen Z., et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density. The Women's Health Initiative Randomized Trial. JAMA 290 (2003) 1729-1738
19. Chlebowski R.T., Wactawski-Wende J., Ritenbaugh C., et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 350 (2004) 991-1004
20. Hsia J., Criqui M.H., Rodabough R.J., et al. Estrogen plus progestin and the risk of peripheral arterial disease. The Women's Health Initiative. Circulation 109 (2004) 620-626
21. McDonough P. The randomized world is not without its imperfections: reflections on the Women's Health Initiative Study. Fertil Steril 78 (2002) 951-956
22. MacLennan A., and Sturdee D. The end of WISDOM. Climacteric 5 (2002) 313-316
23. Hemminki E., Hovi S.L., Veerus P., Tuimala R., Rahu M., and Hakama M. Impact of blinding on recruitment-The Estonian Postmenopausal Hormone Therapy Trial. J Clin Epidemiol 57 (2004) 1237-1243
24. Vickers M., Meade T., and Darbyshire J. WISDOM: history and early demise-was it inevitable?. Climacteric 5 (2002) 317-325
25. International Statistical Classification of Diseases and Related Health Problems, 1989 Revision. Geneva: World Health Organization; 1992.
26. Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
27. Rapp S.R., Espeland M.A., Shumaker S.A., et al. Effect of estrogen plus progestin on global cognitive function in postmenopausal women. The Women's Health Initiative Memory Study: a randomized controlled trial. JAMA 289 (2003) 2663-2672
28. Hays J., Ockene J.K., Brunner R.L., et al. Effects of estrogen plus progestin on health-related quality of life. N Engl J Med 348 (2003) 1839-1854
29. Anderson G.L., Judd H.L., Kaunitz A.M., et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures. The Women's Health Initiative randomized trial. JAMA 290 (2003) 1739-1748
30. Lang K., Mägi M., and Aareleid T. Study of completeness of registration at the Estonian cancer registry. Eur J Cancer Prev 12 (2003) 153-156
31. Estonian Health Insurance Fund. Available at: http://www.haigekassa.ee/HK/in_english.htm. Accessed October 14, 2004.
32. The R Project for Statistical Computing. Available at: http://www.r-project.org. Accessed August 9, 2005.
33. Nelson H.D., Humphrey L.L., Nygren P., Teutsch S.M., and Allan J.P. Postmenopausal hormone replacement therapy. Scientific review. JAMA 288 (2002) 872-881
34. Torgerson D.J., and Bell-Seyer S.E. Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials. JAMA 285 (2001) 2891-2897
35. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 275 (1996) 1389-1396
36. Grodstein F., Newcomb P.A., and Stampfer M.J. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med 106 (1999) 574-582
37. Hovi S.L., Karttunen T., Karro H., and Hemminki E. Comparison of Estonian and Finnish physicians' opinions of menopause and hormone therapy. Maturitas 49 (2004) 107-113
38. Williams J.G., Cheung W.Y., Cohen D.R., Hutchings H.A., Longo M.F., and Russell I.T. Can randomised trials rely on existing electronic data? A feasibility study to explore the value of routine data in health technology assessment. Health Technol Assess 7 (2003) 1-117
39. Thorp J.M., Gavin N.I., and Ohsfeldt R.L. Hormone replacement therapy in postmenopausal women: utilization of health care resources by new users. Am J Obstet Gynecol 185 (2001) 318-326
40. Vorobjov S., Hovi S.-L., Veerus P., Pisarev H., Rahu M., and Hemminki E. Treatment adherence in the Estonian postmenopausal hormone therapy (EPHT) trial [ISRCTN35338757]. Maturitas 52 (2005) 286-295